.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Express Scripts
US Army
Harvard Business School
Federal Trade Commission
QuintilesIMS
Cipla
Healthtrust
Cantor Fitzgerald
Chubb

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208524

« Back to Dashboard

NDA 208524 describes BELVIQ XR, which is a drug marketed by Eisai Inc and is included in one NDA. It is available from one supplier. There are fifteen patents protecting this drug and one Paragraph IV challenge. Additional details are available on the BELVIQ XR profile page.

The generic ingredient in BELVIQ XR is lorcaserin hydrochloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lorcaserin hydrochloride profile page.

Summary for 208524

Tradename:1
Applicant:1
Ingredient:1
Patents:15
Formulation / Manufacturing:see details

Pharmacology for NDA: 208524

Suppliers and Packaging for NDA: 208524

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524 NDA Eisai Inc. 62856-535 62856-535-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (62856-535-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength20MG
Approval Date:Jul 15, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:Jun 27, 2017
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:► SubscribePatent Expiration:Apr 10, 2023Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
Patent:► SubscribePatent Expiration:Apr 10, 2023Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Deloitte
Moodys
Dow
Farmers Insurance
Novartis
Covington
Fuji
Mallinckrodt
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot